drugset
drugset / Trial / NCT03540160

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

NCT03540160 ↗

Phase 3 Terminated 558 enrolled Vyne Therapeutics Inc.
NaSingle-groupOpen-labelTreatment

Summary

Study of the long term safety of serlopitant for the treatment of pruritus in adults.

Timeline

Start
2018-03-15
Primary completion
2020-04-08
Completion
2020-06-17

Outcome

Outcome not reported

Stopped: “No longer pursuing development of serlopitant”

Drugs

EvaluationDrugModalityDoseRoute
Subject Serlopitant Small molecule 5 mg —

Indications

atopic eczema prurigo nodularis psoriasis